Asoxime (HI-6) impact on dogs after one and tenfold therapeutic doses: Assessment of adverse effects, distribution, and oxidative stress

Environmental Toxicology and Pharmacology

Volumn 32, Issue 1, 2011, Pages 75-81

  Pohanka, Miroslav ^a,b   Novotny, Ladislav ^a   Zdarova Karasova, Jana ^a,b   Bandouchova, Hana ^c   Zemek, Filip ^a   Hrabinova, Martina ^a   Misik, Jan ^a   Kuca, Kamil ^a,b   Bajgar, Jiri ^a   Zitka, Ondrej ^d   Cernei, Natalia ^d   Kizek, Rene ^d   Pikula, Jiri ^c  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^d MENDEL UNIVERSITY IN BRNO   (Czech Republic)

Author keywords

Acetylcholinesterase; Antidotum; Butyrylcholinesterase; Nerve agents; Oxime reactivator

Indexed keywords

1 (4 CARBAMOYLPYRIDINIO) 1' (2 HYDROXYIMINOMETHYLPYRIDINIO)DIMETHYL ETHER; ACETYLCHOLINESTERASE; ANTIOXIDANT; CREATINE KINASE; FERRIC REDUCING ANTIOXIDANT; GLUCOSE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG SCREENING; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ACETYLCHOLINESTERASE; ANIMALS; BLOOD GLUCOSE; BLOOD UREA NITROGEN; CHOLINESTERASE REACTIVATORS; CREATINE KINASE; DOGS; GLUTATHIONE; GLUTATHIONE DISULFIDE; HYPERGLYCEMIA; OXIDATIVE STRESS; OXIMES; PYRIDINIUM COMPOUNDS; SULFHYDRYL COMPOUNDS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TRIGLYCERIDES;

CANIS FAMILIARIS;

EID: 79957806269     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2011.03.014     Document Type: Article

References (34)

1. Barthold C.L., Schier J.G. Organic phosphorus compounds - nerve agents. Crit. Care Clin. 2005, 21:673-689.
2. Bajgar J. Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv. Clin. Chem. 2004, 38:151-216.
3. Chen H.C., Bai D.Y., Jiang Y.P. Effects of HI-6 on muscle acetylcholine receptor: analysis on minimal reaction model. Zhongguo Yao Li Xue Bao 1996, 17:428-431.
4. Clement J.G., Bailey D.G., Madill H.D., Tran L.T., Spence J.D. The acetylcholinestearse oxime reactivator HI-6 in man - pharmacokinetics and tolerability in combination with atropine. Biopharm. Drug Dispos. 1995, 16:415-425.
5. Fossier P., Baux G., Poulain B., Tauc L. Receptor-mediated presynaptic facilitation of quantal release of acetylcholine induced by pralidoxime in Aplysia. Cell. Mol. Neurobiol. 1990, 10:383-404.
6. Garcia G.E., Campbell A.J., Olson J., Moorad-Doctor D., Morthole V.I. Novel oximes as blood-brain barrier penetrating cholinesterase reactivators. Chem. Biol. 2010, 187:199-206.
7. Haigh J.R., Adler M., Apland J.P., Deshpande S.S., Barham C.B., Demond P., Koplovitz I., Lenz D.E., Gordon R.K. Protection by pyridostigmine bromide of marmoset hemi-diaphragm acetylcholinesterase activity after soman exposure. Chem. Biol. Interact 2010, 187:416-420.
8. Hamaoui A., Mercado R. Association of preeclampsia and myasthenia: a case report. J. Reprod. Med. 2009, 54:587-590.
9. Jovanovic D., Kovacevic V., Maksimovic M. Pharmacokinetics of the oxime HI-6 from a mixture with atropine sulfate in dogs. Pharmacol. Toxicol. 1992, 71:340-342.
10. Karasova J.Z., Novotny L., Antos K., Zivna H., Kuca K. Time-dependent changes in concentration of two clinically used acetylcholinesterase reactivators (HI-6 and obidoxime) in rat plasma determined by HPLC techniques after in vivo administration. Anal. Sci. 2010, 26:63-67.
11. Kassa J. Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents. J. Toxicol. Clin. Toxicol. 2002, 40:803-816.
12. Kayouka M., Houze P., Risede P., Debray M., Baud F.J. Acute renal failure alters the kinetics of pralidoxime in rats. Toxicol. Lett. 2009, 184:61-66.
13. Kayouka M., Houze P., Debray M., Boud F.J. Acute renal failure enhances the antidotal activity of pralidoxime towards paraoxon-induced respiratory toxicity. Toxicol. Lett. 2009, 189:48-56.
14. Kepner L.A., Wolthuis O.L. A comparison of the oximes HS-6 and HI-6 in the therapy of soman intoxication in rodents. Eur. J. Pharmacol. 1978, 48:377-382.
15. Klimmek R., Eyer P. Pharmacokinetics and pharmacodynamics of the oxime HI6 in dogs. Arch. Toxicol. 1986, 59:272-278.
16. Linster C.L., Van Schaftingen E. Vitamin C. Biosynthesis, recycling and degradation in mammals. FEBS J. 2007, 274:1-22.
17. Loke W.K., Sim M.K., Go M.L. O-substituted derivatives of pralidoxime: muscarinic properties and protection against soman effects in rats. Eur. J. Pharmacol. 2002, 44:279-287.
18. Lundy P.M., Hill I., Lecavalier P., Hamilton M.G., Vair C., Davidson C., Weatherby K.L., Berger B.J. The pharmacokinetics and pharmacodynamics of two HI-6 salts in swine and efficacy in the treatment of GF and soman poisoning. Toxicology 2005, 208:399-409.
19. Lundy P.M., Raveh L., Amitai G. Development of the bisquaternary oxime HI-6 toward clinical use in the treatment of organophosphate nerve agent poisoning. Toxicol. Rev. 2006, 25:231-243.
20. Marrs T.C. Organophosphate poisoning. Pharmacol. Ther. 1993, 58:51-66.
21. McDonough J.H., Van Shura K.E., LaMont J.C., McMonagle J.D., Shih T.M. Comparison of the intramuscular, intranasal or sublingual routes of midazolam administration for the control of soman induced seizures. Basic Clin. Pharmacol. Toxicol. 2009, 104:27-34.
22. Moore D.H., Hayward I.J., Tucker F.S., Kukey B. HI-6 and 2-PAM in sheep: pharmacokinetics and effects on muscle tissue following intramuscular injection. Biopharm. Drug Dispos. 1991, 12:223-232.
23. Nyberg A.G., Cassel G., Jeneskog T., Karlsson L., Larsson R., Lundstrom M., Palmer L., Persson S.A. Pharmacokinetics of HI-6 and atropine in anesthetized pigs after administration by a new autoinjector. Biopharm. Drug Dispos. 1995, 16:635-651.
24. Pohanka M., Jun D., Kuca K. Improvement of acetylcholinesterase based assay for organophosphates in way of identification by reactivators. Talanta 2008, 77:451-454.
25. Pohanka M., Bandouchova H., Sobotka J., Sedlackova J., Soukupova I., Pikula J. Comparison of ferric reducing antioxidant power and square wave voltammetry for assay of low molecular weight antioxidants in blood plasma: performance and comparison of methods. Sensors 2009, 9:9094-9103.
26. Pohanka M., Karasova J.Z., Musilek K., Kuca K., Kassa J. Effect of five acetylcholinesterase reactivators on tabun intoxicated rats: induction of oxidative stress versus reactivation efficacy. J. Appl. Toxicol. 2009, 29:483-488.
27. Pohanka M., Pavlis O., Pikula J., Treml F., Kuca F. Modulation of tularemia disease progress by the bisquaternary pyridinium oxime HI-6. Acta Vet. Brno 2010, 79:443-448.
28. Pohanka M., Pejchal J., Horackova S., Kuca K., Bandouchova H., Damkova V., Pikula J. Modulation of ionising radiation generated oxidative stress by HI-6 (asoxime) in a laboratory rat model. Neuroendocrinol. Lett. 2010, 31(2):62-68.
29. Pohanka M., Sobotka J., Jilkova M., Stetina R. Oxidative stress after sulfur mustard intoxication and its reduction by melatonin: efficacy of antioxidant therapy during serious intoxication. Drug Chem. Toxicol. 2011, 34:85-91.
30. Prozorovski V.B., Livanov G.A., Velikova V.D., Afanasev V.V., Pavlova L.V. Aminostigmine as a cholinesterase inhibitor and as an agent for treating poisonings by cholinergic blockers. Eksp. Klin. Farmakol. 1994, 7:13-15.
31. Sakurada K., Matsubara K., Shimizu K., Shiono H., Seto Y., Tsuge K., Yoshino M., Sakai I., Mukoyama H., Takatori T. Pralidoxime iodide (2-PAM) penetrates across the blood-brain barrier. Neurochem. Res. 2003, 28:1401-1407.
32. Soukup O., Pohanka M., Tobin G., Jun D., Fusek J., Musilek K., Marek J., Kassa J., Kuca K. The effect of HI-6 on cholinesterases and on the cholinergic system of the rat bladder. Neuroendocrinol. Lett. 2008, 29:759-762.
33. Vrdoljak A.L., Berend S., Zeljezic D., Piljac-Zegarac J., Plestina S., Kuca K., Radic B., Mladinic M., Kopjar N. Irinotecan side effects relieved by the use of HI-6 oxime: in vivo experimental approach. Basic Clin. Pharmacol. Toxicol. 2009, 105:401-409.
34. Worek F., Eyer P., Aurbek N., Szinicz L., Thiermann H. Recent advances in evaluation of oxime efficacy in nerve agent poisoning by in vitro analysis. Toxicol. Appl. Pharmacol. 2007, 219:226-234.